Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
8/26/25 Eli Lilly (LLY) Orforglipron for Obesity Subscribers Only Subscribers Only Subscribers Only
8/25/25 argenx (ARGX) Vyvgart for Myasthenia Gravis (MG) Subscribers Only Subscribers Only Subscribers Only
8/21/25 NicOx (COX) NCX 470 for Glaucoma / Ocular Hypertension (Ophthalmology) Subscribers Only Subscribers Only Subscribers Only
8/19/25 Viking Therapeutics (VKTX) VK2735 for Obesity Subscribers Only Subscribers Only Subscribers Only
8/18/25 Reunion RE104 for Postpartum Depression (PPD) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/02/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update